Dr. Reddy's Laboratories SA

About Dr. Reddy's Laboratories SA

Dr. Reddy’s Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets ac...

Certifications
  • CH
  • 2015
    On CPHI since
  • 3
    Certificates
  • 5000+
    Employees
Company types
Generics/Biosimilars Manufacturer
Primary activities
API Producer
Chemical Development
Generic APIs producer
Pharmaceutical Company (generic finished products)
Contact info
Meet us at

CPHI Barcelona 2023

Fira Barcelona Gran Via, Spain
24-26 October 2023

Products from Dr. Reddy's Laboratories SA (5)

  • Losartan Potassium

    Product Losartan Potassium

    Dr. Reddy’s has the capabilities and capacities to manufacture and deliver sartan APIs in accordance with global regulations. Our team of experts developed processes and the analytical methods to avoid the presence of nitrosamine impurities, which are already suitable to confirm future requirements of ...
  • Valsartan

    Product Valsartan

    Dr. Reddy’s has the capabilities and capacities to manufacture and deliver sartan APIs in accordance with global regulations. Our team of experts developed processes and the analytical methods to avoid the presence of nitrosamine impurities, which are already suitable to confirm future requirements of ...
  • Irbesartan

    Product Irbesartan

    Dr. Reddy’s has the capabilities and capacities to manufacture and deliver Irbesartan APIs in accordance with global regulations. Our team of experts developed processes and the analytical methods to avoid the presence of nitrosamine impurities, which are already suitable to confirm future requirements...
  • Telmisartan

    Product Telmisartan

    Dr. Reddy’s has the capabilities and capacities to manufacture and deliver Telmisartan in accordance with global regulations. Our team of experts developed processes and the analytical methods to avoid the presence of nitrosamine impurities, which are already suitable to confirm future requirements of ...
  • Active pharmaceutical ingredients (APIs)

    Product Active pharmaceutical ingredients (APIs)

    High quality APIs to accelerate your generic product launches. Catering to leading innovator and generic companies across the world, Dr. Reddy’s is recognized as one of the largest API suppliers worldwide. The launch of Dr. Reddy’s XCEED – a digital customer service platform - gives customers inst...

Dr. Reddy's Laboratories SA Resources (5)

  • News Pharma Explained: Active Pharmaceutical Ingredients

    What are APIs? As the name suggests, Active Pharmaceutical Ingredients (APIs) are the heart of any dosage form, whether they are oral, injectable or inhaled, and are absolutely essential to the development of a formulated product.
  • Brochure Dabired (Dabigatran Pellets)

    Dabired is ready to fill Dabigatran Etexilate Mesylate 42.04% w/w pellets which are designed to integrate seamlessly into your encapsulation process.
  • Whitepaper Sacubitril/Valsartan (LCZ696) Whitepaper

    This whitepaper outlines Dr. Reddy’s development and characterization approach for the API and how formulation success and early market reach can be facilitated.
  • Video Innovation Across Borders: How Pharma and innovators are fighting back against COVID-19 and ways forward

    A global pandemic demands a fast response. The research-based pharmaceutical industry is working upstream at extraordinary speed to develop a safe and effective vaccine for COVID19. Pharmaceutical companies around the globe are joining forces and speeding up the process by conducting phases and development in parallel and forging new partnerships and collaboration. The pharmaceutical and life science industry has faced the need to leverage science and technology, developed pre and during the pandemic. Firms are coming up with new ways to maintain production despite disrupted supply chains, or they are mobilizing to design new products as demand for existing products collapses. This discussion will examine how the COVID-19 pandemic is driving pharma and life science companies to collaborate, innovate and prepare for an uncertain future. This webinar was originally aired as part of the CPHI Festival of Pharma.
  • Webinar Strengthening Diversity, Equity, and Inclusion in Pharma

    The pharma industry is aware that it needs to improve the representation of women and minority communities in its businesses. The benefits of diverse teams are clear, yet it isn’t an easy road. How can companies create an environment where people feel safe, thrive, and attract the best?
    Approaching Diversity and Inclusion as part of a wider Sustainability / Environment, Social, and Governance (ESG) performance is an essential indicator of pharma companies' commitment to driving I&D for a more diverse and successful workplace, which ultimately also ensures to better serve patients around the world.